#73. The Triumph of Daraxonrasib

Episode 30

0:00-18:51

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind this molecular trap to emerging clinical promise in pancreatic and other KRAS-driven cancers, the daraxonrasib FDA approval reveals a potential turning point in precision oncology—while examining resistance, patient selection, and what KRAS teaches us about drugging the seemingly impossible. Produced by Dr. Jake Chen.

Publisher

Drug Discovery AI Talk

Link

podcasters.spotify.com/pod/show/jakechen/episodes/73--The-Triumph-of-Daraxonrasib-e3oauo6

Published

September 11, 2026

Duration

19 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Dr. Jake Chen

DD

Drug Discovery AI Talk

@drugdiscoveryaitalk

#triumph #daraxonrasib

The Nile